A Novel Potent and Selective Histamine H₃ Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, and Wake-Promoting and Procognitive Effects in Rodents^[S]

Noriko Hino, Toshiyuki Marumo, Makiko Kotani, Toshiharu Shimazaki, Ayaka Kaku-Fukumoto, Hirohiko Hikichi, Jun-ichi Karasawa, Yasumitsu Tomishima, Hiroko Komiyama, Emi Tatsuda, Dai Nozawa, Toshio Nakamura, and Shigeyuki Chaki

Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Saitama, Japan

Received June 26, 2020; accepted August 10, 2020

ABSTRACT

Histamine H₃ receptor antagonists/inverse agonists are known to enhance the activity of histaminergic neurons in the brain, thereby promoting arousal and cognition. Here, we report the in vitro and in vivo pharmacological profiles for a newly synthesized histamine H₃ receptor antagonist/inverse agonist: [1-(4-{3-[(2*R*)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1*H*-pyrazol-4-yl](morpholin-4-yl)methanone monohydrochloride (enerisant hydrochloride). In vitro assays showed that enerisant was a competitive antagonist/inverse agonist with a high affinity and selectivity for human and rat histamine H₃ receptors. Enerisant showed antagonist activity in vivo, as assessed using *R*- α -methylhistamine (a histamine H₃ receptor agonist)-induced dipsogenia, and occupied the histamine H₃ receptor in the frontal cortex in a dose-dependent manner. Enerisant also enhanced the extracellular levels of histamine in the posterior hypothalamus and the levels of dopamine and acetylcholine in the medial prefrontal cortex of rats. Enerisant exerted a procognitive effect or reversed scopolamine-induced cognitive impairment in a social recognition test and a novel object recognition test in rats at doses at which less than 50% of the histamine H₃ receptor were

occupied (0.03–0.3 mg/kg, p.o.). In contrast, higher doses (3–10 mg/kg, p.o.) at which nearly all the histamine H₃ receptors were occupied were needed to exert wake-promoting effects in rats. These results indicate that enerisant is a potent and selective histamine H₃ receptor antagonist/inverse agonist with the potential to promote arousal and procognition in rats. Moreover, the results also suggest that the histamine H₃ receptor occupancy required to exert a pharmacological effect may vary depending on the domain that is being tested.

SIGNIFICANCE STATEMENT

Enerisant is a novel histamine H₃ receptor antagonist/inverse agonist that exerts wake-promoting and procognitive effects in addition to increasing the release of neurotransmitters related to these pharmacological effects in rodents. Moreover, an in vivo receptor binding study revealed that the in vivo occupancy of the histamine H₃ receptor required to exert the pharmacological effects of enerisant varied, and such variations in required occupancy should be taken into account when performing dose selection in clinical studies.

Introduction

The histaminergic system in the central nervous system is implicated in sleep/wake regulation, attention, cognition, and metabolic homeostasis via four subtypes of histamine receptors (H₁, H₂, H₃, and H₄ receptors), all of which belong to a family of G protein-coupled receptors (Leurs et al., 2011). Of these, the histamine H₃ receptor is highly and widely localized in the brain, particularly in areas involved in arousal and cognitive processes such as the cerebral cortex, hippocampus, basal ganglia, and hypothalamus (Martinez-Mir et al., 1990; Lovenberg et al., 1999; Drutel et al., 2001). In these regions,

the histamine H₃ receptor functions as an autoreceptor and/or a heteroreceptor to modulate the release of several neurotransmitters in a negative manner (Arrang et al., 1983; Esbenshade et al., 2008). Conversely, histamine H₃ receptor blockade reportedly enhances the release of multiple neurotransmitters involved in arousal, vigilance, alertness, and cognition (Bacciottini et al., 2002; Giannoni et al., 2010).

Because of the variety of roles that the histamine H₃ receptor plays in neurotransmission, considerable efforts have been expended to develop histamine H₃ receptor antagonists/inverse agonists as potential therapeutic agents for the treatment of sleep/wake disorders such as narcolepsy as well as attention-deficit hyperactivity disorder, Alzheimer's disease, schizophrenia, and other disorders associated with cognitive impairment (Fox et al., 2003, 2005; Ligneau et al., 2007; Medhurst et al., 2007; Esbenshade et al., 2012; Raddatz

The authors declare no outside funding for this work.

<https://doi.org/10.1124/jpet.120.000185>.

[S] This article has supplemental material available at jpet.aspetjournals.org.

ABBREVIATIONS: BSA, bovine serum albumin; CHO, Chinese hamster ovary; CSF, cerebrospinal fluid; EEG, electroencephalogram; enerisant hydrochloride, [1-(4-{3-[(2*R*)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1*H*-pyrazol-4-yl](morpholin-4-yl)methanone monohydrochloride; GTP γ S, guanosine 5'-(γ -thio)triphosphate; mPFC, medial prefrontal cortex; RID, ratio of investigation duration; SD, Sprague-Dawley; TASP0410461, 6-[(1-cyclobutylpiperidin-4-yl)oxy]-1-(5-fluoropyridin-3-yl)-3,4-dihydroquinolin-2(1*H*)-one.

et al., 2012). To date, however, most clinical trials using histamine H₃ receptor antagonists/inverse agonists have failed, despite numerous potent compounds having been synthesized and tested preclinically (Ghamari et al., 2019). Pitolisant, however, has been approved for the treatment of narcolepsy and excessive daytime sleepiness (Javaheri and Javaheri, 2020; Lamb, 2020).

Although the efficacies of numerous histamine H₃ receptor antagonists/inverse agonists have been tested in many pre-clinical studies, few reports have thoroughly compared the direct relations between receptor occupancy and several domains of pharmacological actions (Miller et al., 2009; Esbenshade et al., 2012). Antagonists have been shown to exhibit differing relationships between behavioral efficacy and the levels of histamine H₃ receptor occupancy when the histamine H₃ receptor occupancy was evaluated by using an appropriate radiolabeled ligand for detecting in vivo receptor binding (Miller et al., 2009). Therefore, delineating the appropriate receptor occupancy for different pharmacological effects is important. Moreover, because the determination of histamine H₃ receptor occupancy using in vivo receptor binding is analogous to positron emission tomography imaging studies in clinical settings, the results obtained can be applicable and beneficial to clinical development by enabling the optimal doses to be determined and tested for specific disorders.

We recently synthesized a novel, selective and potent histamine H₃ receptor antagonist/inverse agonist: [1-(4-{3-[(2*R*)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1*H*-pyrazol-4-yl](morpholin-4-yl)methanone monohydrochloride (enerisant hydrochloride). First, we characterized the in vitro profiles and the pharmacological effects of enerisant, including its wake-promoting and procognitive effects. We also used a radiolabeled ligand ([³H]TASP0410461) that can be used to label the histamine H₃ receptor in vivo to determine the histamine H₃ receptor occupancy of enerisant, enabling the pharmacological actions of enerisant to be examined in relation to histamine H₃ receptor occupancy.

Materials and Methods

Animal. Male Sprague-Dawley (SD) rats (7–13 weeks; Charles River, Yokohama, Japan) were used to evaluate in vivo binding of histamine H₃ receptor to investigate *R*- α -methylhistamine-induced drinking behavior and for the electroencephalogram (EEG) studies and the spontaneous locomotor activity test. Male Wistar rats (9–10 weeks; Charles River) were used for the novel object recognition test. For the social recognition test, adult male SD rats (9 weeks) or juvenile male SD rats (4 weeks) were used. C57BL/6J mice (7 weeks; Charles River) were used to evaluate spontaneous locomotor activity. All the animals were maintained under 12-hour light/dark cycles (lights on at 7:00 AM) in a temperature- and humidity-controlled holding room, with food and water available ad libitum.

All the animal study protocols were approved by the Animal Care and Use Committee of Taisho Pharmaceutical Co., Ltd. and the EEG studies were approved by the Institutional Animal Ethics Committee of NISSEI BILIS Co., Ltd.

Drugs. [1-(4-{3-[(2*R*)-2-Methylpyrrolidin-1-yl]propoxy}phenyl)-1*H*-pyrazol-4-yl](morpholin-4-yl)methanone monohydrochloride (enerisant hydrochloride) (Fig. 1) was synthesized at Taisho Pharmaceutical Co., Ltd., and dissolved in dimethyl sulfoxide for the in vitro studies and in saline or distilled water for the in vivo studies. [³H]6-[(1-cyclobutylpiperidin-4-yl)oxy]-1-(5-fluoropyridin-3-yl)-3,4-dihydroquinolin-2(1*H*)-one (TASP0410461) (specific radioactivity: 524 GBq/mmol) was synthesized at Sekisui Medical Co., Ltd. (Tokyo,

Japan). [³H]N- α -methylhistamine (specific radioactivity: 3156 GBq/mmol), [³⁵S]guanosine 5'-(γ -thio)triphosphate (GTP γ S) (specific radioactivity: 46.25 TBq/mmol), and Chinese hamster ovary (CHO)-K1 cells expressing human H₃ receptor were purchased from PerkinElmer Inc. (Waltham, MA). *R*- α -methylhistamine dihydrobromide was purchased from Tocris Bioscience (Bristol, UK). Thioperamide maleate, GTP γ S, *R*- α -methylhistamine dihydrochloride, and scopolamine hydrochloride were purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan). Donepezil hydrochloride was purchased from Eisai Co., Ltd. (Tokyo, Japan).

Radioligand Receptor Binding Assays for Histamine H₃ Receptor. The affinity of enerisant for the histamine H₃ receptor was determined using [³H]N- α -methylhistamine binding to the membranes of CHO-K1 cells expressing human recombinant H₃ receptor (for human histamine H₃ receptor) or the membranes of rat cerebral cortex (for rat histamine H₃ receptor). Membrane preparations in 50 mmol/l Tris-HCl buffer (pH 7.4) containing 5 mmol/l EDTA and 0.1% (w/v) bovine serum albumin (BSA) were incubated with [³H]N- α -methylhistamine (1 nmol/l for CHO-K1 cells; 0.75 nmol/l for rat cerebral cortex) in the presence or absence of increasing concentrations (0.001–10,000 nmol/l) of enerisant at 25°C for 1 hour. Nonspecific binding was determined in the presence of *R*- α -methylhistamine (10 μ mol/l) for the CHO-K1 cells or thioperamide (10 μ mol/l) for the rat cerebral cortex. We used *R*- α -methylhistamine to determine non-specific binding for human histamine H₃ receptor according to the manufacturer's technical data sheet (PerkinElmer Inc.). The reaction mixtures were filtered by rapid filtration under a vacuum through a UniFilter GF/C microplate (PerkinElmer Inc.) presoaked with 0.3% (w/v) polyethyleneimine, after which the filters were washed with 50 mmol/l Tris-HCl buffer (pH 7.4) containing 5 mmol/l EDTA using a Cell harvester. The filter-bound radioactivity was counted using a TopCount NXT (PerkinElmer Inc.). The experiments were performed in duplicate. Specific binding was determined by subtracting the nonspecific binding from the total binding. The K_i value was calculated using the equation K_i = IC₅₀/(1 + (L/K_d)), where L is the concentration of [³H]N- α -methylhistamine and K_d was determined using various concentrations of the radioligand. When the binding mode of enerisant to the histamine H₃ receptor was investigated, [³H]N- α -methylhistamine binding was conducted using various concentrations of [³H]N- α -methylhistamine (0.25, 0.5, 1, 2, 4, 8, 16 nmol/l) in the absence or presence of enerisant (3 and 10 nmol/l), and the K_d and B_{max} values were determined using a nonlinear least-squares curve-fitting procedure.

Additional Receptor Bindings and Enzyme Assays. The affinity of enerisant to other histamine receptor subtypes (H₁, H₂, and H₄ receptors) was evaluated using respective binding assays for each of the human recombinant receptors (Sekisui Medical Co., Ltd., Ibaraki, Japan). Enerisant was run against a panel of 66 receptor binding assays and 45 enzyme assays (Cerep, Le Bois l'Évêque, France) according to previously reported methods. Enerisant was tested in duplicate at 1 and 10 μ mol/l.

[³⁵S]GTP γ S Binding Assay for Histamine H₃ Receptor. The antagonist and inverse agonist activities of enerisant were determined by examining [³⁵S]GTP γ S binding to the membranes of CHO-K1 cells expressing human recombinant histamine H₃ receptor (for human histamine H₃ receptor) or the membranes of rat frontal cortex (for rat

Fig. 1. Chemical structure of enerisant hydrochloride.

histamine H₃ receptor). For human histamine H₃ receptor, membrane preparations in 20 mmol/l HEPES buffer (pH 7.4) containing 100 mmol/l NaCl, 3 mmol/l MgCl₂, 10 µg/ml saponin, 0.1% (w/v) BSA, and 3 µmol/l GDP were incubated with increasing concentrations (0.001–10,000 nmol/l) of ennerisant in the presence or absence of *R*-α-methylhistamine (30 nmol/l) at 30°C for 20 minutes, after which the reaction mixtures were further incubated with [³⁵S]GTPγS (0.2 nmol/l) at 30°C for 30 minutes. Nonspecific binding was determined in the presence of GTPγS (10 µmol/l) instead of *R*-α-methylhistamine. For the rat histamine H₃ receptor, membrane preparations in 20 mmol/l HEPES buffer (pH 7.4) containing 100 mmol/l NaCl, 10 mmol/l MgCl₂, 30 µg/ml saponin, 0.1% (w/v) BSA, 300 µmol/l GDP and 1 U/ml adenosine deaminase were incubated with increasing concentrations (0.001–10,000 nmol/l) of ennerisant in the presence or absence of *R*-α-methylhistamine (295 nmol/l) at 30°C for 20 minutes, after which the reaction mixtures were further incubated with [³⁵S]GTPγS (0.3 nmol/l) at 30°C for 90 minutes. Nonspecific binding was determined in the presence of GTPγS (10 µmol/l) instead of *R*-α-methylhistamine. The reaction was terminated as described for [³H]N-α-methylhistamine binding. The inverse agonist activity of ennerisant was determined using the same experimental conditions except for the absence of *R*-α-methylhistamine in the reaction mixtures.

***R*-α-Methylhistamine-Induced Dipsogenia in Rats.** Male SD rats were placed in a five-compartment stainless-steel cage and were habituated with free access to food and water before the test. Water was provided through a stainless-steel sipper connected to a silicon-based tube with a 10 ml syringe. Ennerisant hydrochloride was orally administered 1 hour before the intraperitoneal injection of *R*-α-methylhistamine dihydrochloride (3 mg/kg). Access to food was stopped, and the amount of water that was subsequently consumed was recorded for 1 hour immediately after *R*-α-methylhistamine dihydrochloride injection.

Histamine H₃ Receptor In Vivo Binding. The histamine H₃ receptor occupancy of ennerisant was determined by the in vivo binding of [³H]TASP0410461, a histamine H₃ receptor antagonist/inverse agonist, which is a radioligand suitable for labeling the histamine H₃ receptor in vivo (Supplemental Fig. 1). Male SD rats were administered [³H]TASP0410461 (740 kBq/ml, 1 ml/kg) through the tail vein at 1 hour after the oral administration of ennerisant hydrochloride (0.1, 0.3, 1, and 3 mg/kg). Thirty minutes after the injection of [³H]TASP0410461, the rats were sacrificed, and the frontal cortex was dissected. In addition, the cerebellum, which is a region with low levels of histamine H₃ receptor, was dissected from the vehicle-treated rats and was used to determine non-specific binding. The tissues were then homogenized in ice-cold 50 mmol/l Tris-HCl buffer (pH 7.4) containing 5 mmol/l EDTA, and the homogenates were filtered over GF/B glass microfiber filters presoaked with 0.3% (w/v) polyethyleneimine solution, after which the filters were washed with the buffer. The percentage receptor occupancy of ennerisant was determined by its ability to compete for the in vivo binding of [³H]TASP0410461 in the frontal cortex and was calculated using the following formula:

$$\text{Receptor occupancy of ennerisant (\%)} = (1 - A/B) \times 100,$$

where A is the [³H]TASP0410461-specific binding after each dose of ennerisant hydrochloride administration, and B is the [³H]TASP0410461-specific binding after vehicle administration.

The ED₅₀ value of each test substance was determined from each dose-response curve by nonlinear least-squares curve-fitting procedure.

Microdialysis Experiments. Male SD rats were secured to a brain stereotaxic apparatus under anesthesia with sodium pentobarbital, and a guide cannula (AG-12 for histamine or AG-4 for dopamine and acetylcholine; Eicom Corporation, Kyoto, Japan) was inserted into the posterior hypothalamus (for histamine, AP: -4.3 mm, L: 1.3 mm, V: 7.2 mm from the bregma) or the medial prefrontal cortex (for dopamine and acetylcholine, AP: +3.2 mm, L: 0.8 mm, V: 1 mm) according to the brain atlas of Paxinos and Watson (1997); the

cannula was fixed in place using the cap nut. The rats were allowed to recover for at least 2 days and were habituated to the sound-proof test cage from the day before the test. A microdialysis probe (A-I-12-02 membrane length 2 mm for histamine, A-I-4-03 membrane length 3 mm for dopamine and acetylcholine; Eicom Corporation) was inserted into the guide cannula and was fixed in place using cap nut under isoflurane (histamine) or ether (dopamine and acetylcholine) anesthesia. On the test day, Ringer's solution (flow rate 2 µl/min for histamine and dopamine, 1 µl/min for acetylcholine) was perfused, and dialysate samples were continuously collected at 12-minute (for histamine), 10-minute (for dopamine), or 20-minute (for acetylcholine) intervals. The dialysate samples were automatically and directly injected into the high-performance liquid chromatography–fluorometry (for histamine) or high-performance liquid chromatography–electrochemical detector (for dopamine and acetylcholine) via an autoinjector. The mean value of histamine levels of five dialysate samples (for histamine) or three dialysate samples (for dopamine and acetylcholine) before the administration of ennerisant hydrochloride was defined as the basal level. Dialysate sampling was continued for 180 minutes after the administration of ennerisant hydrochloride. The levels in the dialysate samples were determined according to Eicom's technical documents.

EEG Sleep/Wake Study. The EEG studies were conducted at NISSEI BILIS Co., Ltd., Shiga Laboratory (Koka, Japan). Male SD rats chronically implanted with EEG electrodes were kept in a measurement cage placed in a soundproof shielded room (light period: 7:00–19:00), and EEG measurements were recorded 24 hours prior to drug administration. Ennerisant hydrochloride (1, 3, and 10 mg/kg) was orally administered at around 11:00, and EEG measurements were recorded until 7 hours after the administration of ennerisant hydrochloride. Spontaneous EEG and electromyogram signals were extracted from the electroencephalographs and entered into a frequency analysis program (MTS50061A; Nihon Santeku Co., Ltd, Osaka, Japan) running on a personal computer, and the EEG image signal was inputted into the EEG video system (VY301B; Nihon Kohden Corporation Co., Ltd., Tokyo, Japan). Based on the EEG produced by the EEG frequency analysis program, the sleep/wake cycle was visually analyzed in 20-second epochs for each sleep stage [awake, rest, slow-wave light sleep, slow-wave deep sleep, and fast-wave sleep (rapid eye movement sleep)]. The total duration of each stage every hour was then determined. Locomotor activity was measured using a passive infrared sensor locomotor activity measurement system (Supermex; Muromachi Kikai Co., Ltd., Tokyo, Japan).

Novel Object Recognition Test. The novel object recognition test was performed according to a previously reported method with modifications (Karasawa et al., 2008). The experiments were performed using a transparent open field box measuring 45 × 27 × 30 cm. Male Wistar rats were placed in a test box in which two objects had been placed in two corners. The time spent exploring each object was recorded during the subsequent 5-minute period (defined as the training session). After 2 hours, the rats were placed in the test box once again, and one of the familiar objects used in the previous training session was replaced with a novel object. The time spent exploring each object was then recorded during a 5-minute period (defined as the test session). The time spent exploring each object was measured manually by experimenters who were unaware of the treatments. A preference index, consisting of the ratio of the amount of time spent exploring any one of the two objects (during the training session) or the replaced novel one (during the test session) relative to the total time spent exploring both objects, was used to measure memory preference. Twenty minutes before the training session, scopolamine hydrochloride (0.3 mg/kg, i.p.) was administered, and ennerisant hydrochloride (0.03, 0.1 and 0.3 mg/kg) or donepezil hydrochloride (1 mg/kg) was administered orally at 1 hour before the training session.

Social Recognition Test. The social recognition test was performed according to a previously reported method (Shimazaki et al., 2010). The experiments were performed using an open-topped box

(45 × 27 × 30 cm). An adult rat and an unfamiliar juvenile rat were placed in the test cage, and the length of time during which the adult rat exhibited exploratory behavior (sniffing, grooming, and close following) toward the juvenile rat was recorded (first investigation duration). After 85 minutes, the adult was placed in the same test cage and habituated for 30 minutes, after which the same juvenile (familiar) was placed in the test cage once again for a 5-minute test session; the length of time spent by the adult in exploring the juvenile during this test session was measured (second investigation duration). The time spent exploring the juvenile rats was measured manually by experimenters who were unaware of the treatments. The social memory for each adult rat was defined by determining the ratio of the duration of the second investigation to that of the first investigation [ratio of investigation duration (RID)]. Enerisant hydrochloride (0.01, 0.03, and 0.1 mg/kg) or donepezil hydrochloride (0.3 mg/kg) was administered orally immediately after the first investigation. When the effect of enerisant on scopolamine-impaired social memory was investigated, adult rats were trained in a social memory test to recall prior exposure to a conspecific juvenile, as described above, but with the following changes: the two 5-minute investigation periods were separated by only 30 minutes; enerisant hydrochloride or donepezil hydrochloride was administered to the adult rats orally 1 hour prior to the first investigation, and scopolamine hydrochloride was administered to the adult rats intraperitoneally 30 minutes prior to the first investigation.

Spontaneous Locomotor Activity of Rats and Mice. Animals were placed individually in transparent open-topped vinyl chloride or acrylic cages (for rats, 47 × 28 × 30 cm; for mice, 30 cm diameter, 30 cm height), and spontaneous locomotor activity was recorded for 1 hour using a SCANET apparatus (Melquest Ltd, Toyama, Japan) placed in a sound-proof box. Enerisant hydrochloride (0.3, 3, and 30 mg/kg) was administered orally 1 hour before the start of the measurement.

Pharmacokinetic Analyses. To evaluate the exposure levels of enerisant in the plasma, brain, and cerebrospinal fluid (CSF) after systemic administration, enerisant hydrochloride (1, 3, and 10 mg/kg) was orally administered to male SD rats. The animals were sacrificed, and blood, CSF, and brain samples were collected at 0.5, 1, 2, 3, and 7 hours after the administration of enerisant hydrochloride. Each sample was extracted using protein precipitation and was subsequently analyzed to determine the enerisant levels using a liquid chromatography/tandem mass spectrometry-qualified research method on an API4000 instrument (SCIEX, Framingham, MA).

Statistical Analysis. For the *in vivo* study, data were generally analyzed by applying the F-test or Bartlett's test to examine the homogeneity in variance, followed by Student's *t* test (for comparisons between two groups) and Dunnett's test or Steel's test (for multiple comparisons). For the novel object recognition test and the social recognition test, data were analyzed using Student's *t* test for comparisons between the two groups and a one-way analysis of variance for multiple comparisons followed by the Dunnett's test. All the statistical analyses were performed using SAS system version 8.2 (SAS Institute Japan, Tokyo, Japan). A value of *P* < 0.05 was regarded as significant.

Results

In Vitro Profiles. The affinity of enerisant for the histamine H₃ receptor was determined by evaluating [³H]N- α -methylhistamine binding to the membranes of CHO-K1 cells expressing human histamine H₃ receptor or the membranes of rat cerebral cortex. Enerisant had a high affinity for the histamine H₃ receptor, with IC₅₀ values of 2.89 (2.57–3.26) nmol/l for human histamine H₃ receptor and 14.5 (10.1–20.8) nmol/l for rat histamine H₃ receptor (Table 1). K_i values of enerisant computed were 1.65 ± 0.05 nmol/l (for human histamine H₃ receptor) and 7.87 ± 0.65 nmol/l (for rat

histamine H₃ receptor), respectively. Enerisant, at concentrations of 3 and 10 nmol/l, increased the K_d value without changing the B_{max} value of [³H]N- α -methylhistamine binding to rat histamine H₃ receptor (Fig. 2), showing that enerisant competitively inhibits [³H]N- α -methylhistamine binding. Enerisant inhibited *R*- α -methylhistamine-stimulated [³⁵S]GTP γ S binding to human histamine H₃ receptor and rat histamine H₃ receptor with IC₅₀ values of 1.06 (0.166–6.78) and 10.5 (4.79–22.8) nmol/l, respectively, indicating that enerisant acts as an antagonist at the histamine H₃ receptor (Table 1). Moreover, enerisant inhibited basal [³⁵S]GTP γ S binding to human histamine H₃ receptor with an EC₅₀ value of 0.357 (0.196–0.650) nmol/l, indicating that enerisant acts as an inverse agonist at the histamine H₃ receptor (Table 1). In contrast, enerisant had negligible effects on binding to human histamine H₁, H₂, and H₄ receptor subtypes (Table 1). Moreover, enerisant displayed negligible affinities for 66 other receptors, transporters, and ion channels at concentrations of 1 and 10 μ mol/l, whereas it inhibited approximately 50% of receptor bindings for some receptors at 10 μ mol/l (Supplemental Table 1). Enerisant displayed negligible effects on 45 enzymes at concentrations of 1 and 10 μ mol/l (Supplemental Table 2). Therefore, enerisant is a potent and selective antagonist/inverse agonist of histamine H₃ receptor.

Rat Dipsogenia Model. The histamine H₃ receptor agonist *R*- α -methylhistamine increases water intake, and this effect has been reported to be mediated through the central histamine H₃ receptor (Lecklin et al., 1998; Fox et al., 2002). Thus, this model was used to evaluate the *in vivo* antagonist activity of enerisant. In this study, *R*- α -methylhistamine dihydrochloride (3 mg/kg, *i.p.*) produced a dipsogenia response in rats (*P* < 0.0001), and the oral administration of enerisant hydrochloride attenuated the dipsogenia response, reaching statistical significance at doses of 0.3 mg/kg (*P* = 0.0002) and 1 mg/kg (*P* = 0.0001) (Fig. 3).

In Vivo Histamine H₃ Receptor Occupancy in the Frontal Cortex of Rats. The histamine H₃ receptor occupancy of enerisant was determined by evaluating the *in vivo* receptor binding of [³H]TASP0410461 in the frontal cortex, a brain region where the histamine H₃ receptor is highly expressed. The oral administration of enerisant hydrochloride resulted in the occupancy of the histamine H₃ receptor in a dose-dependent manner (Fig. 4). A dose eliciting a half-maximal receptor occupancy of enerisant hydrochloride was calculated to be 0.78 mg/kg.

In Vivo Neurotransmitter Release. The effects of enerisant on the extracellular levels of histamine in the posterior hypothalamus, of dopamine in the medial prefrontal cortex (mPFC), and of acetylcholine in the mPFC were evaluated using microdialysis in freely moving rats. The subcutaneous administration of enerisant hydrochloride increased the total extracellular histamine levels in the posterior hypothalamus, and an analysis of the total percent of change at each time point after enerisant hydrochloride administration also indicated significant differences between the enerisant hydrochloride-treated (1 mg/kg, *s.c.*) and vehicle-treated groups (*P* = 0.0083, Fig. 5A). The intraperitoneal administration of enerisant hydrochloride increased the total extracellular dopamine levels in the mPFC, and an analysis of the total percent of change at each time point also indicated significant differences between the enerisant hydrochloride-treated (3 mg/kg, *i.p.*) and the vehicle-treated groups (*P* = 0.005, Fig. 5B).

TABLE 1

In vitro activity of ennerisant at histamine receptor subtypes
Data represent means [95% confidence interval] obtained from three separate experiments (H₃) or a single experiment (H₁, H₂, and H₄).

	IC ₅₀ or EC ₅₀ (nmol/l)				
	Human H ₁	Human H ₂	Human H ₃	Human H ₄	Rat H ₃
Affinity	>10,000	>10,000	2.89 [2.57–3.26]	>10,000	14.5 [10.1–20.8]
Antagonist activity			1.06 [0.166–6.78]		10.5 [4.79–22.8]
Inverse agonist activity			0.357 [0.196–0.650]		

Moreover, the intraperitoneal administration of ennerisant hydrochloride increased the total extracellular acetylcholine levels in the mPFC, and an analysis of the total percent of change at each time point also indicated significant differences between the ennerisant hydrochloride-treated (1 mg/kg, i.p.) and the vehicle-treated groups ($P = 0.0017$, Fig. 5C).

Rat EEG Sleep/Wake Activity. Compared with vehicle treatment, the oral administration of ennerisant hydrochloride significantly increased wakefulness at doses of 3 mg/kg ($P < 0.01$) and 10 mg/kg ($P < 0.01$) and decreased slow-wave light sleep at doses of 3 mg/kg ($P < 0.01$) and 10 mg/kg ($P < 0.01$) for 2 hours after administration, whereas ennerisant hydrochloride significantly decreased slow-wave deep sleep at doses of 1 mg/kg ($P < 0.01$), 3 mg/kg ($P < 0.05$) and 10 mg/kg ($P < 0.01$) (Fig. 6). Ennerisant hydrochloride (1, 3 and 10 mg/kg, p.o.) did not affect the accumulated locomotor activity time at up to 7 hours after administration (data not shown).

Novel Object Recognition Test in Rats. Scopolamine hydrochloride-treated rats spent significantly less time exploring a novel object, compared with vehicle-treated rats ($P < 0.0001$) (Fig. 7A), indicating that scopolamine impaired object memory in rats. Treatment with donepezil hydrochloride (1 mg/kg, p.o.) significantly inhibited the scopolamine-induced impairment of object memory ($P = 0.0005$) (Fig. 7A).

Likewise, ennerisant hydrochloride (0.3 mg/kg, p.o.) significantly attenuated the impairment of object memory induced by scopolamine ($P = 0.0001$) (Fig. 7A).

Social Recognition Test in Rats. Rats treated with donepezil hydrochloride (0.3 mg/kg, p.o.) exhibited a significantly shorter RID ($P = 0.004$) (Fig. 7B). Likewise, rats treated with ennerisant hydrochloride (0.1 mg/kg, p.o.) exhibited a significantly shorter RID ($P = 0.0093$) (Fig. 7B). When the two 5-minute investigation periods were separated by 30 minutes, the second investigation period of each adult rat toward the same juvenile rat decreased, suggesting that the adult rats retained a social memory of the juvenile rats that were investigated during the first period. The social memory was impaired by treatment with scopolamine hydrochloride ($P = 0.0008$), which was prevented by pretreatment with donepezil hydrochloride (0.3 mg/kg, p.o.) ($P < 0.0001$) (Fig. 7C). Likewise, scopolamine-impaired social memory was significantly attenuated by pretreatment with ennerisant hydrochloride ($P = 0.0016$ for 0.03 mg/kg, p.o. and $P = 0.0046$ for 0.1 mg/kg, p.o.) (Fig. 7C).

Spontaneous Locomotor Activity in Rats and Mice. The oral administration of ennerisant hydrochloride did not significantly affect spontaneous locomotor activity in rats or mice at doses of 0.3–30 mg/kg (Fig. 8).

Fig. 2. Analysis of the binding mode of ennerisant to histamine H₃ receptor using membranes of rat cerebral cortex. (Upper) Linear regression lines in the absence or presence of 3 or 10 nmol/l of ennerisant were estimated using the least-squares procedure. Data represent the means $\pm$ S.E. of results obtained from three separate experiments. (Lower) Dissociation constant (K_d) and maximum binding (B_{max}) of [³H]N- α -methylhistamine-specific binding to membranes of rat cerebral cortex. Data represent the means $\pm$ S.E. of results obtained from three separate experiments.

	Control	Ennerisant (3 nmol/L)	Ennerisant (10 nmol/L)
Kd (nmol/L)	1.28 $\pm$ 0.0365	1.64 $\pm$ 0.0890	3.78 $\pm$ 0.584
Bmax (fmol/mg protein)	123.1 $\pm$ 9.615	102.8 $\pm$ 6.961	117.3 $\pm$ 7.835

Fig. 3. Effect of ennerisant hydrochloride on *R*- α -methylhistamine-induced dipsogenia in rats. Water intake was measured for 1 hour immediately after the intraperitoneal administration of *R*- α -methylhistamine or saline (control). Ennerisant hydrochloride or the vehicle was orally administered 1 hour before the intraperitoneal administration of *R*- α -methylhistamine. Data represent the means $\pm$ S.E. ($N = 15/\text{group}$). ** $P < 0.01$, compared with response to control group (Student's t test). ## $P < 0.01$, compared with response to vehicle-treated group (Steel's test).

Pharmacokinetic Profiles of Enerisant. The plasma, brain, and CSF levels of ennerisant after the oral administration of ennerisant hydrochloride are summarized in Table 2. The levels of ennerisant increased in a greater than dose-proportional manner. Ennerisant rapidly reached a maximal level (C_{max}) in plasma within 1 to 2 hours after administration, whereas the levels in the plasma, brain, and CSF were practically equal between 1 and 2 hours after administration at all the doses that were tested. The concentration of ennerisant in CSF was 5.17 ng/ml (13.0 nmol/l), which is close to the *in vitro* affinity (IC_{50} value) for histamine H_3 receptor, at 1 hour after the oral administration of 1 mg/kg of ennerisant hydrochloride.

Discussion

In the present study, ennerisant was shown to be a potent and selective histamine H_3 receptor antagonist/inverse agonist with wake-promoting and procognitive effects in rodents. Furthermore, ennerisant requires different degrees of histamine H_3 receptor occupancy in the frontal cortex to exert these pharmacological effects. *In vivo* studies of ennerisant are summarized in Table 3.

In vitro studies showed that ennerisant is a potent, highly selective, and competitive antagonist for the histamine H_3 receptor with a more than 3000-fold selectivity over other histamine receptor subtypes. In addition, ennerisant exhibits an inverse agonist activity at the histamine H_3 receptor, as observed with other histamine H_3 receptor antagonists described to date (Esbenshade et al., 2004; Ligneau et al., 2007; Raddatz et al., 2012). It should be noted that ennerisant, like other nonimidazole compounds (Esbenshade et al., 2004, 2012; Raddatz et al., 2012), had higher affinity (approximately 5-fold) and more potent antagonist activity (approximately 10-fold) for human histamine H_3 receptor than for rat histamine H_3 receptor, and that this is in contrast with imidazole-containing histamine H_3 receptor antagonists/inverse agonists (Esbenshade et al., 2004), which are less potent at human histamine H_3 receptor than at rat histamine H_3 receptor. It should be additionally mentioned that ennerisant

has higher selectivity over histamine receptor subtypes and $\sigma 1$ receptor than pitolisant (Ligneau et al., 2007; Riddy et al., 2019). *In vivo* functional blockade of the central histamine H_3 receptor by ennerisant was demonstrated using a previously characterized *R*- α -methylhistamine-induced dipsogenia model (Lecklin et al., 1998; Fox et al., 2002). Thus, the oral administration of ennerisant hydrochloride inhibited *R*- α -methylhistamine-induced dipsogenia in rats. *In vivo* histamine H_3 receptor antagonism was also demonstrated by evaluating histamine release in the posterior hypothalamus. Since the histamine H_3 receptor functions as an autoreceptor on histaminergic somata and presynaptic terminals to provide a tonic inhibition of the firing rate of histamine neurons (Haas and Panula, 2003) and histamine release (Arrang et al., 1983), histamine H_3 receptor antagonists/inverse agonists increase the histamine levels in the synaptic cleft. Ennerisant increased the extracellular histamine levels in the posterior hypothalamus, as measured using a microdialysis technique, indicating histamine H_3 receptor antagonism. Collectively, these results show that ennerisant is a potent, selective, and competitive antagonist/inverse agonist of the histamine H_3 receptor with excellent *in vivo* antagonist activity, thereby increasing histaminergic activity.

Histamine H_3 receptor blockade also increases the release of other neurotransmitters in a regionally and functionally specific manner that is dependent on histaminergic innervation and the localization of histamine H_3 receptors. As observed for other histamine H_3 receptor antagonists/inverse agonists, ennerisant was shown to increase the releases of acetylcholine and dopamine in the mPFC in the present study. Thus, ennerisant increases the extracellular concentrations of neurotransmitters such as histamine, acetylcholine, and dopamine, which are important for vigilance and cognition.

In vivo receptor binding, rather than *ex vivo* receptor binding, has been proposed to be advantageous for determining the *in vivo* receptor occupancy because the results of *ex vivo* binding might underestimate the degree of *in vivo* receptor occupancy as a result of dissociation during *ex vivo* procedures, as demonstrated for other receptor ligands (Kapur et al., 2001) as well as the histamine H_3 receptor ligand

Fig. 4. Histamine H_3 receptor occupancy by ennerisant in the frontal cortex of rats. Histamine H_3 receptor occupancy (%) in the frontal cortex was measured 30 minutes after the intravenous administration of [^3H]TASP0410461. Ennerisant hydrochloride or the vehicle was orally administered 1 hour before the injection of [^3H]TASP0410461. Data represent the means $\pm$ S.E. ($N = 5/\text{group}$).

Fig. 5. Effect of ennerisant hydrochloride on extracellular levels of histamine, dopamine and acetylcholine in brain regions of rats. (A) Effect of ennerisant hydrochloride on extracellular histamine levels in the posterior hypothalamus. (Upper) Time course of histamine levels (%) sampled over 12-minute intervals from 48 minutes before to 180 minutes after the administration of ennerisant hydrochloride or the vehicle. The vertical arrow indicates the time of drug administration. (Lower) Total histamine levels were defined as the cumulative percent of the baseline value over a 180-minute period. Data represent the means $\pm$ S.E. of results obtained from six rats/group. $**P < 0.01$, compared with the response to the vehicle-treated group (Dunnett's test). (B) Effect of ennerisant hydrochloride on extracellular dopamine levels in the medial prefrontal cortex. (Upper) Time course of dopamine levels (%) sampled over 10-minute intervals from 20 minutes before to 180 minutes after the administration of ennerisant hydrochloride or the vehicle. The vertical arrow indicates the time of drug administration. (Lower) Total dopamine levels were defined as the cumulative percent of the baseline value over a 180-minute period. Data represent the means $\pm$ S.E. of results obtained from five rats/group. $**P < 0.01$, compared with the response to the vehicle-treated group (Dunnett's test). (C) Effect of ennerisant hydrochloride on extracellular acetylcholine levels in the medial prefrontal cortex. (Upper) Time course of acetylcholine levels (%) sampled over 20-minute intervals from 40 minutes before to 180 minutes after the administration of ennerisant hydrochloride or the vehicle. The vertical arrow indicates the time of drug administration. (Lower) Total acetylcholine levels were defined as the cumulative percent of the baseline value over a 180-minute period. Data represent the means $\pm$ S.E. of results obtained from six to eight rats/group. $**P < 0.01$, compared with the response to the vehicle-treated group (Dunnett's test).

(Le et al., 2008). In the present study, we determined the histamine H₃ receptor occupancy in the brain by utilizing a newly synthesized radiolabeled ligand, [³H]TASP0410461, and obtained results showing that the oral administration of ennerisant hydrochloride resulted in a dose-dependent histamine H₃ receptor occupancy in the frontal cortex with an ED₅₀

value of 0.78 mg/kg. The in vivo antagonism of ennerisant was observed at doses (0.3 and 1 mg/kg) resulting in less than or nearly 50% histamine H₃ receptor occupancy, and this finding is consistent with previous findings for another histamine H₃ receptor antagonist/inverse agonist ABT-239 (Fox et al., 2005; Miller et al., 2009). Moreover, the concentration of ennerisant in

Fig. 6. Effect of ennerisant hydrochloride on sleep/wake cycle of rats. (Upper) Effect of ennerisant hydrochloride on awake levels. The vertical arrow indicates the time of the oral administration of ennerisant hydrochloride or the vehicle. Data represent the means of three rats. (Lower) Effect of ennerisant hydrochloride on each parameter (awake, rest, slow-wave light sleep, slow-wave deep sleep, fast-wave sleep) for 2 hours after administration. Data represent the means $\pm$ S.E. of results obtained from eight rats/group. $*P < 0.05$; $**P < 0.01$, compared with the response to the vehicle-treated group (Dunnett's test).

Fig. 7. Effect of enlerisat hydrochloride in a novel object recognition test (A) and the social recognition test (B and C) in rats. (A) Effect of enlerisat hydrochloride on scopolamine-induced cognitive deficits in the novel object recognition test. Enlerisat hydrochloride, donepezil hydrochloride or the vehicle was orally administered, followed 40 minutes later by the intraperitoneal administration of scopolamine hydrochloride. Data represent the means $\pm$ S.E. ($N = 9-10/\text{group}$). $^{##}P < 0.01$, compared with the response to the vehicle + vehicle-treated group (Student's t test). Enlerisat-treated group: $^{**}P < 0.01$, compared with the response to the vehicle + scopolamine-treated group (Dunnett's test). Donepezil-treated group: $^{**}P < 0.01$, compared with the response to the vehicle + scopolamine-treated group (Student's t test). (B) Effect of enlerisat hydrochloride on time-dependent memory impairment in the social recognition test. Enlerisat hydrochloride, donepezil hydrochloride or the vehicle was orally administered immediately after the first investigation. Data represent the means $\pm$ S.E. ($N = 12-15/\text{group}$). Enlerisat-treated group: $^{**}P < 0.01$, compared with the response to the vehicle-treated group (Dunnett's t test). Donepezil-treated group: $^{**}P < 0.01$, compared with the response to the vehicle-treated group (Student's t test). (C) Effect of enlerisat hydrochloride on scopolamine-induced cognitive deficits in the social recognition test. Enlerisat hydrochloride, donepezil hydrochloride or the vehicle was orally administered 1 hour prior to the first investigation, followed 30 minutes later by the intraperitoneal administration of scopolamine hydrochloride. Data represent the means $\pm$ S.E. ($N = 14-15/\text{group}$). $^{##}P < 0.01$, compared with the response to the vehicle + vehicle-treated group (Student's t test). Enlerisat-treated group: $^{**}P < 0.01$, compared with the response to the vehicle + scopolamine-treated group (Dunnett's test). Donepezil-treated group: $^{**}P < 0.01$, compared with the response to the vehicle + scopolamine-treated group (Student's t test).

CSF was 13.0 nmol/l at 1 hour after the oral administration of 1 mg/kg of enlerisat hydrochloride, at which dose a 50.9% occupancy was observed. This finding is consistent with the in vitro affinity of enlerisat for rat histamine H_3 receptor ($IC_{50} = 14.5$ nmol/l), indicating that the in vivo receptor binding used in the present study corresponds to the in vitro antagonist activity.

Histamine H_3 receptor antagonists/inverse agonists have been reported to increase wakefulness in several species (Fox et al., 2003, 2005; Barbier et al., 2004; Le et al., 2008; Ligneau et al., 2007; Esbenschade et al., 2012; Raddatz et al., 2012). Likewise, in the present study, we observed that enlerisat increased wakefulness and decreased slow-wave light sleep and slow-wave deep sleep in rats. In contrast, the enhanced wakefulness was not accompanied by increased motor activity, which is distinct from that of stimulants such as

amphetamine (Parmentier et al., 2007). Notably, enlerisat increased wakefulness in rats at doses of 3 and 10 mg/kg, at which doses an in vivo receptor binding study showed a histamine H_3 receptor occupancy of more than 80%. The present result was consistent with the previous reports that histamine H_3 receptor antagonists/inverse agonists increased arousal at doses corresponding to nearly full occupancy or more than 80% occupancy of the histamine H_3 receptor (Barbier et al., 2004; Le et al., 2008; Raddatz et al., 2012). Moreover, the present result was consistent with the report that therapeutic dose of pitolisant occupies brain histamine H_3 receptor by more than 80% in humans (Rusjan et al., 2020). In addition, increased wakefulness was observed at a dose at which a significant increase in the extracellular histamine concentration was observed in the posterior hypothalamus, supporting the hypothesis that

Fig. 8. Effect of enlerisat hydrochloride on spontaneous locomotor activity in rats (A) and mice (B). (A) Enlerisat hydrochloride (0.3, 3 and 30 mg/kg) or the vehicle was administered orally to rats prior to the measurement of spontaneous locomotor activity for 1 hour. Data represent the means $\pm$ S.E. ($N = 8/\text{group}$). (B) Enlerisat hydrochloride (0.3, 3 and 30 mg/kg) or the vehicle was administered orally to mice prior to the measurement of spontaneous locomotor activity for 1 hour. Data represent the means $\pm$ S.E. ($N = 8/\text{group}$).

TABLE 2

Plasma, brain, and CSF concentrations of ennerisant after single oral administration of ennerisant hydrochloride in rats

Dose	Time	Plasma	Brain	CSF
mg/kg	h	ng/ml	ng/g	ng/ml
1	0.5	39.2 ± 21.4	10.8 ± 6.80	4.74 ± 3.43
	1	40.2 ± 10.3	13.3 ± 3.01	5.17 ± 1.37
	2	38.9 ± 7.35	13.5 ± 1.78	5.29 ± 1.43
	3	35.6 ± 7.41	12.7 ± 2.94	4.15 ± 0.748
	7	12.4 ± 4.91	5.07 ± 1.50	1.50 ± 0.717
3	0.5	122 ± 49.3	25.5 ± 8.30	13.8 ± 6.00
	1	169 ± 40.4	49.6 ± 14.6	23.6 ± 4.41
	2	176 ± 33.8	48.1 ± 9.10	21.2 ± 4.47
	3	100 ± 29.0	34.5 ± 10.3	13.2 ± 3.51
	7	51.5 ± 15.4	16.2 ± 3.67	5.52 ± 1.76
10	0.5	738 ± 310	179 ± 86.5	110 ± 52.0
	1	802 ± 115	218 ± 50.8	115 ± 28.4
	2	745 ± 219	218 ± 90.4	94.8 ± 28.8
	3	488 ± 78.0	135 ± 21.5	66.9 ± 11.3
	7	208 ± 81.2	56.5 ± 23.0	28.1 ± 15.6

histamine H₃ receptor antagonists/inverse agonists increase wakefulness by increasing histaminergic tones.

Potential cognition-enhancing properties of ennerisant were examined in two behavioral tests, a novel object recognition test and a social recognition test, both of which have been used to evaluate the procognitive effects of several agents (de Bruin and Pouzet, 2006; Loiseau et al., 2008; Shimazaki et al., 2010; Chaki et al., 2015). In the present study, ennerisant significantly reversed cognitive impairment induced by scopolamine in both a novel object recognition test and the social recognition test. In addition, ennerisant significantly enhanced social memory in naïve animals. These results complement previous findings of a procognitive effect of histamine H₃ receptor antagonists/inverse agonists (Fox et al., 2005; Medhurst et al., 2007; Esbenshade et al., 2012; Griebel et al., 2012; Raddatz et al., 2012; Alachkar et al., 2017). Interestingly, although the effective dose varies, these effects occurred at doses corresponding to a histamine H₃ receptor occupancy of less than 30.7% under all the conditions used in this study. In particular, in the social recognition test, the procognitive effects appeared at receptor occupancy levels of 12.6% or less. The present results were consistent with previous findings that histamine H₃ receptor antagonists/inverse agonists exert procognitive effects at doses corresponding to a smaller percentage of occupancy (as low as 10%) and that do not affect wake/sleep EEG (Fox et al., 2003, 2005; Miller et al., 2009;

Esbenshade et al., 2012). The present and previous studies clearly indicate that a much lower receptor occupancy is sufficient for histamine H₃ receptor antagonists/inverse agonists to exert their procognitive effects, at least in rodents. Not only acetylcholine, but also dopaminergic transmission in the frontal cortex is presumably involved in the procognitive effects observed in the above-mentioned models (Millan et al., 2007; Loiseau and Millan, 2009; Pezze et al., 2015), suggesting that the increased release of acetylcholine and dopamine in the mPFC by ennerisant may contribute to the procognitive effects in these animal models. Although significant increases in these neurotransmitter levels were seen at doses higher than those efficacious in the novel object recognition test and the social recognition test, it is likely that only subtle, localized changes are required to exert procognitive effects. In this regard, these discrepancies may reflect the limited sensitivity of microdialysis techniques, which do not measure subtle changes in synaptic cleft neurotransmitter levels.

Notably, it has been demonstrated that histaminergic neurons are organized into distinct functional circuits impinging on different brain regions, and that responses to histamine H₃ receptor antagonists differentiate histaminergic neurons according to their projection areas (Blandina et al., 2012). Therefore, it can be conceivable that histaminergic activity in the brain regions relating to arousal and cognition may be

TABLE 3

Summary of the effects of ennerisant in animal models

Values represents MED in each model except in vivo H₃ receptor occupancy, which shows ED₅₀ value.

Model	Species	MED or ED ₅₀
In vivo H ₃ receptor occupancy	Rat	0.78 mg/kg (p.o.)
In vivo antagonism		
<i>R</i> -α-methylhistamine-induced dipsogenia	Rat	0.3 mg/kg (p.o.)
Neurotransmitter release		
Histamine release in the posterior hypothalamus	Rat	1 mg/kg (s.c.)
Dopamine release in the mPFC	Rat	3 mg/kg (i.p.)
Acetylcholine release in the mPFC	Rat	1 mg/kg (i.p.)
EEG sleep/wake activity		
Wakefulness	Rat	3 mg/kg (p.o.)
Cognition		
Novel object recognition test (scopolamine)	Rat	0.3 mg/kg (p.o.)
Social recognition test (natural forgetting)	Rat	0.1 mg/kg (p.o.)
Social recognition test (scopolamine)	Rat	0.03 mg/kg (p.o.)
Spontaneous locomotor activity	Mouse, Rat	>30 mg/kg (p.o.)

MED, minimum effective dose.

differentially regulated by enelisant, which may partly account for differential pharmacological actions of enelisant.

In summary, the present study demonstrates potent pharmacological effects after oral dosing with enelisant hydrochloride and suggests that this novel histamine H₃ receptor antagonist/inverse agonist may have therapeutic utility in the treatment of sleep and cognitive disorders. We also provide evidence that the histamine H₃ receptor occupancy required to exert each effect differs. The present results will provide important information in planning and interpreting clinical studies of enelisant, which will facilitate future mechanism-related studies as well as validations of the effectiveness of this approach in patients exhibiting histamine H₃ receptor abnormalities.

Authorship Contributions

Participated in research design: Hino, Chaki.

Conducted experiments: Hino, Marumo, Kotani, Shimazaki, Kaku-Fukumoto, Hikichi, Karasawa, Tomishima, Komiyama, Tatsuda, Chaki.

Contributed new reagents or analytic tools: Nozawa, Nakamura.

Performed data analysis: Hino, Marumo, Hikichi.

Wrote or contributed to the writing of the manuscript: Hino, Chaki.

References

- Alachkar A, Łazewska D, Kieć-Kononowicz K, and Sadek B (2017) The histamine H₃ receptor antagonist E159 reverses memory deficits induced by dizocilpine in passive avoidance and novel object recognition paradigm in rats. *Front Pharmacol* **8**: 709 DOI: 10.3389/fphar.2017.00709.
- Arrang JM, Garbarg M, and Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H₃) of histamine receptor. *Nature* **302**:832–837.
- Bacciottini L, Passani MB, Giovannelli L, Cangioni I, Mannaioni PF, Schunack W, and Blandina P (2002) Endogenous histamine in the medial septum-diagonal band complex increases the release of acetylcholine from the hippocampus: a dual-probe microdialysis study in the freely moving rat. *Eur J Neurosci* **15**:1669–1680.
- Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur C, Pudiak CM, et al. (2004) Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H₃ antagonist. *Br J Pharmacol* **143**:649–661.
- Blandina P, Munari L, Provensi G, and Passani MB (2012) Histamine neurons in the tuberomammillary nucleus: a whole center or distinct subpopulations? *Front Syst Neurosci* **6**:33.
- Chaki S, Shimazaki T, Karasawa J, Aoki T, Kaku A, Iijima M, Kambe D, Yamamoto S, Kawakita Y, Shibata T, et al. (2015) Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia. *Psychopharmacology (Berl)* **232**:2849–2861.
- de Bruin N and Pouzet B (2006) Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. *Pharmacol Biochem Behav* **85**:253–260.
- Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H, Panula P, and Leurs R (2001) Identification of rat H₃ receptor isoforms with different brain expression and signaling properties. *Mol Pharmacol* **59**:1–8.
- Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, and Brioni JD (2008) The histamine H₃ receptor: an attractive target for the treatment of cognitive disorders. *Br J Pharmacol* **154**:1166–1181.
- Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, et al. (2012) Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H₃ receptor antagonist. *J Pharmacol Exp Ther* **343**:233–245.
- Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, et al. (2004) Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H₃ receptor antagonist. *Biochem Pharmacol* **68**:933–945.
- Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl-benzofuran-5-yl}benzonitrile)] II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H₃ receptor antagonist. *J Pharmacol Exp Ther* **313**:176–190.
- Fox GB, Pan JB, Esbenshade TA, Bitner RS, Nikkel AL, Miller T, Kang CH, Bennani YL, Black LA, Faghhi R, et al. (2002) Differential in vivo effects of H₃ receptor ligands in a new mouse dipsogenia model. *Pharmacol Biochem Behav* **72**:741–750.
- Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghhi R, Bennani YL, Williams M, Yao BB, et al. (2003) Two novel and selective nonimidazole H₃ receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. *J Pharmacol Exp Ther* **305**:897–908.
- Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, and Hamzeh-Mivehroud M (2019) Histamine H₃ receptor antagonists/inverse agonists: where do they go? *Pharmacol Ther* **200**:69–84.
- Giannoni P, Medhurst AD, Passani MB, Giovannini MG, Ballini C, Corte LD, and Blandina P (2010) Regional differential effects of the novel histamine H₃ receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. *J Pharmacol Exp Ther* **332**: 164–172.
- Griebel G, Pichat P, Pruniaux MP, Beeské S, Lopez-Grancha M, Genet E, Terranova JP, Castro A, Sánchez JA, Black M, et al. (2012) SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents. *Pharmacol Biochem Behav* **102**:203–214.
- Haas H and Panula P (2003) The role of histamine and the tuberomammillary nucleus in the nervous system. *Nat Rev Neurosci* **4**:121–130.
- Javaheri S and Javaheri S (2020) Update on persistent excessive daytime sleepiness in OSA. *Chest* **158**:776–786 Available from: 10.1016/j.chest.2020.02.036.
- Kapur S, Barlow K, VanderSpek SC, Javanmard M, and Nobrega JN (2001) Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. *Psychopharmacology (Berl)* **157**:168–171.
- Karasawa J, Hashimoto K, and Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. *Behav Brain Res* **186**:78–83.
- Lamb YN (2020) Pitolisant: a review in narcolepsy with or without cataplexy. *CNS Drugs* **34**:207–218.
- Le S, Gruner JA, Mathiasen JR, Marino MJ, and Schaffhauser H (2008) Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H₃ receptor antagonists. *J Pharmacol Exp Ther* **325**:902–909.
- Lecklin A, Etu-Seppälä P, Stark H, and Tuomisto L (1998) Effects of intracerebroventricularly infused histamine and selective H₁, H₂ and H₃ agonists on food and water intake and urine flow in Wistar rats. *Brain Res* **793**:279–288.
- Leurs R, Vischer HF, Wiltmans M, and de Esch IJ (2011) En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. *Trends Pharmacol Sci* **32**:250–257.
- Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anacleto C, Lin JS, et al. (2007) BF2.649 [1-[3-(4-Chlorophenyl)propyl]propyl]piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H₃ receptor: preclinical pharmacology. *J Pharmacol Exp Ther* **320**:365–375.
- Loiseau F, Dekeyne A, and Millan MJ (2008) Pro-cognitive effects of 5-HT₆ receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. *Psychopharmacology (Berl)* **196**:93–104.
- Loiseau F and Millan MJ (2009) Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. *Eur Neuro-psychopharmacol* **19**:23–33.
- Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, and Erlander MG (1999) Cloning and functional expression of the human histamine H₃ receptor. *Mol Pharmacol* **55**:1101–1107.
- Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, and Palacios JM (1990) Three histamine receptors (H₁, H₂ and H₃) visualized in the brain of human and non-human primates. *Brain Res* **526**:322–327.
- Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, et al. (2007) GSK189254, a novel H₃ receptor antagonist that binds to histamine H₃ receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. *J Pharmacol Exp Ther* **321**:1032–1045.
- Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, and Gobert A (2007) Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. *J Neurochem* **100**: 1047–1061.
- Miller TR, Milicic I, Bauch J, Du J, Surber B, Browman KE, Marsh K, Cowart M, Brioni JD, and Esbenshade TA (2009) Use of the H₃ receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H₃ receptor antagonists. *Br J Pharmacol* **157**:139–149.
- Parmentier R, Anacleto C, Guhenec C, Brousseau E, Bricout D, Giboulot T, Bozyczko-Coyne D, Spiegel K, Ohtsu H, Williams M, et al. (2007) The brain H₃-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. *Biochem Pharmacol* **73**:1157–1171.
- Paxinos G and Watson C (1997) *The Rat Brain in Stereotaxic Coordinates*, 3rd ed, Academic press, San Diego, CA.
- Pezze MA, Marshall HJ, Fone KC, and Cassaday HJ (2015) Dopamine D1 receptor stimulation modulates the formation and retrieval of novel object recognition memory: role of the prelimbic cortex. *Eur Neuropsychopharmacol* **25**:2145–2156.
- Raddatz R, Hudkins RL, Mathiasen JR, Gruner JA, Flood DG, Aimone LD, Le S, Schaffhauser H, Duzic E, Gasior M, et al. (2012) CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. *J Pharmacol Exp Ther* **340**:124–133.
- Riddy DM, Cook AE, Shackleford DM, Pierce TL, Mocaer E, Mannoury la Cour C, Sors A, Charman WN, Summers RJ, Sexton PM, et al. (2019) Drug-receptor kinetics and sigma-1 receptor affinity differentially clinically evaluated histamine H₃ receptor antagonists. *Neuropharmacology* **144**:244–255.
- Rusjan P, Sabioni P, Di Ciano P, Mansouri E, Boileau I, Laveillé A, Capet M, Duvauchelle T, Schwartz JC, Robert P, et al. (2020) Exploring occupancy of the histamine H₃ receptor by pitolisant in humans using PET. *Br J Pharmacol* **177**: 3464–3472.
- Shimazaki T, Kaku A, and Chaki S (2010) D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. *Psychopharmacology (Berl)* **209**:263–270.

Address correspondence to: Dr. Shigeyuki Chaki, Research Headquarters, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan. E-mail: s-chaki@taisho.co.jp